Literature DB >> 18663736

Prospective double-blind crossover trial of ibuprofen in reducing EMG pain.

Khalid El-Salem1, Mohammad Shakhatreh.   

Abstract

To test the efficacy of ibuprofen in reducing needle electromyography (EMG) pain we studied 30 healthy volunteers randomized to receive placebo or ibuprofen (400 mg) 2 h before EMG using concentric needle electrodes in four muscles. The electromyographer and volunteer were both blinded. Immediately after EMG, subjects reported their experience of pain on a visual analog scale (VAS). A day later, they filled a VAS for their memory of pain during EMG and a VAS for the residual pain at needle sites. A week later, subjects were crossed over and the same procedure was repeated on the same muscles of the contralateral limbs. Immediate recall of pain was significantly decreased by ibuprofen, but memory of pain and residual needle site pain a day after EMG were not decreased. We conclude that ibuprofen is effective in reducing EMG pain as perceived immediately after the procedure. Premedication with ibuprofen before EMG is useful.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18663736     DOI: 10.1002/mus.21017

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  3 in total

1.  Patient perception of pain versus observed pain behavior during a standardized electrodiagnostic test.

Authors:  Josh Verson; Andrew J Haig; Danielle Sandella; Karen S J Yamakawa; Zachary London; Christy Tomkins-Lane
Journal:  Muscle Nerve       Date:  2014-12-16       Impact factor: 3.217

2.  Factors influencing aversion to specific electrodiagnostic studies.

Authors:  Nivedita U Jerath; Scott B Strader; Chandan G Reddy; Andrea Swenson; Jun Kimura; Edward Aul
Journal:  Brain Behav       Date:  2014-07-22       Impact factor: 2.708

3.  The provision of written information and its effect on levels of pain and anxiety during electrodiagnostic studies: A randomised controlled trial.

Authors:  Yan Ling Lai; Annemarie Van Heuven; Adeniyi Borire; Tejaswi Kandula; James G Colebatch; Arun V Krishnan; William Huynh
Journal:  PLoS One       Date:  2018-05-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.